乳腺癌是全球女性主要的恶性肿瘤，对全球死亡率有贡献。有不计其数的异常基因负责多因素致癌途径。尽管已检测到多个致病突变，治疗通常侧重于减轻疾病的表现，而不是协调目标区域中的突变。然而，CRISPR-Cas系统作为一种DNA修饰工具的出现，证明了它是乳腺癌治疗的有希望的基因编辑工具。因此，在本文中，我们讨论了CRISPR-Cas系统所针对的不同信号转导途径，并探讨了它们在乳腺癌治疗中的作用。我们还试图全面覆盖CRISPR-Cas9介导的乳腺癌基因敲除。在本文中，还描述了影响细胞信号通路的乳腺癌细胞的许多变化。本文将为乳腺癌中CRISPR-Cas介导的治疗靶向提供全面的知识。版权所有 © 2023 Elsevier B.V. 发表。

Breast cancer represents the prevailing malignancy in females and contributing towards mortality on a global scale. There are innumerable anomalous genes that are responsible in the multi factorial carcinogenesis pathway. Although several disease-causing mutations have been detected, therapy frequently focuses on attenuating the manifestation of the disease rather than harmonizing the mutation in the target area. However, the emergence of the CRISPR-Cas system as a DNA modifying tool has proved to be a promising gene editing tool for breast cancer therapeutics. Henceforth, in this review, we have discussed different signaling pathways that have been targeted by the CRISPR-Cas system and explored their role in breast cancer therapies. We have also tried to comprehensively cover CRISPR-Cas9 mediated gene knockout in breast cancer. In this review many alterations in breast cancer cells that affect cell signaling pathways have also been described. This review will be a valuable addition to providing comprehensive knowledge of CRISPR-Cas mediated therapeutic targeting in breast cancer.Copyright © 2023. Published by Elsevier B.V.